| Old Articles: <Older 5831-5840 Newer> |
|---|
 |
The Motley Fool
August 19, 2009
Brian Orelli |
Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.   |
The Motley Fool
August 19, 2009
Brian Orelli |
Amgen's Climbing Up the Ladder Positive trial data should help sales. |
AskMen.com
Nick Kennedy |
The Health Care Debate: The Basics The real debate that's sucking the air out of the country and turning cozy town hall meetings into WWE smackdowns is the issue of health care reform. |
InternetNews
August 17, 2009 |
Patients Warm to Digital Records, Docs Shun Web It's hit-and-miss for the latest trends in health IT, according to findings from a new IBM study. |
The Motley Fool
August 17, 2009
Brian Orelli |
Preparing for a Home Run Some good news and bad news for companies selling drugs to treat multiple sclerosis, after Novartis announces Extavia has been approved by the FDA. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Schizophrenic Drug Approval Schering's drug gets a thumbs-up. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
August 14, 2009
Brian Orelli |
Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel. |
BusinessWeek
August 13, 2009
Arlene Weintraub |
Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics. |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
| <Older 5831-5840 Newer> Return to current articles. |
